Doximity lifts revenue outlook on AI tool adoption surge

Doximity's fiscal Q1 2027 results mark a turning point in how the healthcare software company is selling itself to investors. For years, Doximity's pitch has centered on converting deep physician engagement into high-margin software and marketing revenue; the latest earnings cycle adds a credible clinical AI angle to that narrative. The revenue beat—coming in ahead of earlier guidance—and the substantial lift to both second-quarter and full-year targets reflect management confidence that AI tools are not just attracting physicians but translating into monetized contracts.

However, the narrowing of margins and the decline in net income year-on-year inject caution into the bull case. The stock's sharp rebound over the past period has already priced in some optimism around the AI push, and the Simply Wall St Community's fair value estimates—ranging from roughly US$18 to just under US$36.72—demonstrate that investors are far from consensus on how much execution risk to accept. Near-term success will depend on whether large health systems move from pilot to scaled adoption of these AI tools and whether that adoption locks in durable, contracted revenue rather than one-time sales.